We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
TSI, DrFirst Collaborate
News

TSI, DrFirst Collaborate

TSI, DrFirst Collaborate
News

TSI, DrFirst Collaborate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "TSI, DrFirst Collaborate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Translational Software® Inc (TSI) has announced that the company has been selected by DrFirst to enable pharmacogenomics (PGx)-based e-prescribing within the Rcopia® medication management system at the point of care. The partnership will offer Rcopia’s 330+ electronic health record and hospital information system vendors and 62,000 providers a comprehensive solution for prescribing safer and more effective medications based on a patient’s genetic makeup.

TSI’s proprietary knowledge platform and Application Programming Interface (API) will provide genotyping prompts, genomic decision support and critical alerts regarding drug efficacy, toxicity and known interactions within the e-prescribing workflow to guide clinical decision making, minimize adverse reactions and enable physicians to prescribe the most effective medications in real-time. The PGx results can be used throughout the patient’s lifetime to improve treatment decisions and overall population health outcomes. Ordering and reporting will be delivered through Rcopia’s medication adherence tool, Patient Advisor℠.

“Integrating Translational Software’s PGx knowledge base within our e-prescribing platform allows us to deliver an in-workflow, evidence-based approach to medication prescribing that can be used as part of routine care,” stated G. Cameron Deemer, president of DrFirst. “In addition, the API will allow us to cost-effectively scale our efforts and develop a customized, seamless clinician experience for accessing genomic data within Rcopia.”

Developed using the Fast Healthcare Interoperability Resources (FHIR) specification, the API will enable Rcopia’s extensive user base to:

•Identify patients as candidates for genotyping based on the medication being prescribed
•Order recommended PGx tests through Exceltox and Alpha Genomix laboratories
•Review detailed reports that identify potential drug-gene and drug-drug interactions and adverse events, and provide medication alternatives
•Access genetic test results to flag interactions for future medications over the patient’s lifetime

DrFirst’s Rcopia is the leading platform for drug e-prescribing and controlled substance e-prescribing, electronic prior authorization, medication history and medication adherence. It is also the first system in the industry to provide real-time benefit checking to guide cost-effective prescription decisions.

“We have a significant opportunity to drive value-based healthcare throughout the U.S. by eliminating costly and ineffective therapies through use of a genomic e-medication management system at such a large scale,” stated Don Rule, CEO, TSI. “We are very excited to be working with DrFirst to develop an IT infrastructure that makes it possible to improve treatment decisions by providing timely, accessible and actionable genomic information to clinicians as part of their existing workflow.” TSI’s PGx knowledge base and genomic decision support is expected to be available in Rcopia in the first quarter of 2017.

Source: Story from Translational Software® Inc. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.

Advertisement